Oncology focused hospital to initiate Senhance System program
RESEARCH TRIANGLE PARK, N.C., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that a Senhance® Surgical System has been sold to the Company’s distribution partner in Germany focused on Eastern Europe and the Commonwealth of Independent States (CIS) region. The Senhance System will be placed at an end user oncology focused hospital.
“We are very excited about the traction our distribution partner has been able to develop and maintain in this part of the world during what continues to be a turbulent period in time,” said Anthony Fernando, Asensus Surgical President and CEO. “We are especially excited to see hospitals adopt Senhance and use their own capital to do so. This financial commitment demonstrates the Senhance System’s clinical relevance and the value it can deliver.”
Asensus Surgical's technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.
Email Alerts: https://ir.asensus.com/email-alerts
This press release includes statements relating to the Senhance Surgical System and the sale of a Senhance System to a distribution partner, which will be ultimately placed at an end user oncology focused hospital. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the financial commitment by the hospital purchaser demonstrates the Senhance Surgical System’s clinical relevance and the value it can deliver. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on February 28, 2022 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Mark Klausner or Mike Vallie, 443-213-0499
Isabella Rodriguez, 708-833-1572